Niagen Bioscience swings to Q3 net loss of $1.17 million from year-earlier profit

PUBT · 3d ago
Niagen Bioscience swings to Q3 net loss of $1.17 million from year-earlier profit
  • Niagen Bioscience swung to a third-quarter 2026 net loss of $1.17 million from a year-earlier profit.
  • Net sales fell 20% year-over-year to $27.19 million.
  • Quarterly operating cash flow totaled $2.6 million, while cash and cash equivalents ended the quarter at $69.5 million.
  • New launches included ready-to-inject Niagen at-home injections and the Niagen NanoCloud topical skincare product.
  • Management expects operating expenses to increase in 2026 to support strategic investments, with injectables and skincare partnerships becoming meaningful contributors in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001386570-26-000057), on November 04, 2026, and is solely responsible for the information contained therein.